Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.

  title={Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.},
  author={Srinivasa P. S. Rao and Suresh B. Lakshminarayana and Ravinder Reddy Kondreddi and Maxime Herv{\'e} and Luis Felipe Recalde Camacho and Pablo Juan Bifani and Sarath K. Kalapala and Jan Jiricek and Ng L. Ma and Bee Huat Tan and Seow Hwee Ng and Mahesh B Nanjundappa and Sindhu Ravindran and Peck Gee Seah and Pamela Thayalan and Siao H Lim and Boon Heng Lee and Anne Goh and Whitney S Barnes and Zhong Chen and Kerstin Gagaring and Arnab K Chatterjee and Kevin Pethe and Kelli L. Kuhen and John R. Walker and Gu Feng and Sreehari Babu and Lijun Zhang and Francesca Blasco and David Beer and Margaret Weaver and Veronique Anne Dartois and Richard Glynne and Thomas Dick and Paul W Smith and Thierry Tidiane Diagana and Ujjini H Manjunatha},
  journal={Science translational medicine},
  volume={5 214},
New chemotherapeutic compounds against multidrug-resistant Mycobacterium tuberculosis (Mtb) are urgently needed to combat drug resistance in tuberculosis (TB). We have identified and characterized the indolcarboxamides as a new class of antitubercular bactericidal agent. Genetic and lipid profiling studies identified the likely molecular target of indolcarboxamides as MmpL3, a transporter of trehalose monomycolate that is essential for mycobacterial cell wall biosynthesis. Two lead candidates… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 26 extracted citations


Publications referenced by this paper.
Showing 1-10 of 53 references

Design , synthesis , and biological evaluation of indole - 2 - carboxamides : A promising class of antituberculosis agents

  • H. Boshoff, C. S. Dowd, +6 authors C. E. Barry
  • J . Med . Chem .
  • 2013

Similar Papers

Loading similar papers…